LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

Search

Simulations Plus Inc

Open

SectorGezondheidszorg

16.94 -2.36

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

16.91

Max

17.43

Belangrijke statistieken

By Trading Economics

Inkomsten

-70M

-67M

Verkoop

-2.1M

20M

K/W

Sectorgemiddelde

48.528

105.69

Dividendrendement

0.48

Winstmarge

-330.585

Werknemers

243

EBITDA

327K

5.3M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

-7.67% downside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.48%

2.37%

Volgende Winsten

1 dec 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-5.6M

346M

Vorige openingsprijs

19.3

Vorige sluitingsprijs

16.94

Nieuwssentiment

By Acuity

50%

50%

182 / 374 Rangschikking in Healthcare

Simulations Plus Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 nov 2025, 21:55 UTC

Winsten

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

12 nov 2025, 21:34 UTC

Winsten

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

12 nov 2025, 23:44 UTC

Marktinformatie

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

12 nov 2025, 23:38 UTC

Marktinformatie

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

12 nov 2025, 23:13 UTC

Winsten

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

12 nov 2025, 22:30 UTC

Marktinformatie
Winsten

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

12 nov 2025, 22:18 UTC

Winsten

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

12 nov 2025, 22:12 UTC

Marktinformatie

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

12 nov 2025, 22:05 UTC

Winsten

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver 3Q Adj EPS 48c >PAAS

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver 3Q Rev $884.4M >PAAS

12 nov 2025, 22:04 UTC

Winsten

Pan American Silver 3Q EPS 45c >PAAS

12 nov 2025, 22:03 UTC

Winsten

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

12 nov 2025, 22:02 UTC

Winsten

Manulife Financial 3Q Net C$1.8B >MFC

12 nov 2025, 22:02 UTC

Winsten

Manulife Financial 3Q Adj EPS C$1.16 >MFC

12 nov 2025, 22:02 UTC

Winsten

Manulife Financial 3Q EPS C$1.02 >MFC

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

12 nov 2025, 21:53 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

12 nov 2025, 21:52 UTC

Acquisities, Fusies, Overnames

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

12 nov 2025, 21:51 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

12 nov 2025, 21:50 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

12 nov 2025, 21:49 UTC

Winsten

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

12 nov 2025, 21:48 UTC

Winsten

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

12 nov 2025, 21:40 UTC

Winsten

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

Peer Vergelijking

Prijswijziging

Simulations Plus Inc Prognose

Koersdoel

By TipRanks

-7.67% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 16 USD  -7.67%

Hoogste 16 USD

Laagste 16 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Simulations Plus Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Sentiment

By Acuity

182 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat